Click to copy, then share by pasting into your messages, comments, social media posts and websites.
Click to copy, then add into your webpages so users can view and engage with this video from your site.
Report Content
We also accept reports via email. Please see the Guidelines Enforcement Process for instructions on how to make a request via email.
Thank you for submitting your report
We will investigate and take the appropriate action.
JAMA: "MRNA vaccines were associated with increased risk of MYOCARDITIS & PERICARDITIS"
"Conclusions and Relevance Results of this large cohort study indicated that both first and second doses of mRNA vaccines were associated with increased risk of myocarditis and pericarditis."
SOURCE:
https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253
###
Original Investigation
April 20, 2022
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents
Øystein Karlstad, MScPharm, PhD1;
Petteri Hovi, MD, PhD2;
Anders Husby, MD, PhD3,4; et al
Tommi Härkänen, PhD2;
Randi Marie Selmer, MSc, PhD1;
Nicklas Pihlström, MSc5;
Jørgen Vinsløv Hansen, MSc, PhD3;
Hanna Nohynek, MD, PhD6;
Nina Gunnes, MSc, PhD1,7;
Anders Sundström, BA, PhD8;
Jan Wohlfahrt, MSc, DMSC3;
Tuomo A. Nieminen, MSocSc9;
Maria Grünewald, MSc, PhD5;
Hanne Løvdal Gulseth, MD, PhD1;
Anders Hviid, MSc, DMSC3,10;
Rickard Ljung, MD, PhD, MPH8,11
JAMA Cardiol.
Published online April 20, 2022.
doi:10.1001/jamacardio.2022.0583
Question
Is SARS-CoV-2 messenger RNA (mRNA) vaccination associated with risk of myocarditis?
Findings
In a cohort study of 23.1 million residents across 4 Nordic countries, risk of myocarditis after the first and second doses of SARS-CoV-2 mRNA vaccines was highest in young males aged 16 to 24 years after the second dose. For young males receiving 2 doses of the same vaccine, data were compatible with between 4 and 7 excess events in 28 days per 100 000 vaccines after second-dose BNT162b2, and between 9 and 28 per 100 000 vaccines after second-dose mRNA-1273.
Meaning
The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.
Abstract
Importance
Reports of myocarditis after SARS-CoV-2 messenger RNA (mRNA) vaccination have emerged.
Objective
To evaluate the risks of myocarditis and pericarditis following SARS-CoV-2 vaccination by vaccine product, vaccination dose number, sex, and age.
Design, Setting, and Participants
Four cohort studies were conducted according to a common protocol, and the results were combined using meta-analysis. Participants were 23 122 522 residents aged 12 years or older. They were followed up from December 27, 2020, until incident myocarditis or pericarditis, censoring, or study end (October 5, 2021). Data on SARS-CoV-2 vaccinations, hospital diagnoses of myocarditis or pericarditis, and covariates for the participants were obtained from linked nationwide health registers in Denmark, Finland, Norway, and Sweden.
Exposures
The 28-day risk periods after administration date of the first and second doses of a SARS-CoV-2 vaccine, including BNT162b2, mRNA-1273, and AZD1222 or combinations thereof. A homologous schedule was defined as receiving the same vaccine type for doses 1 and 2.
Main Outcomes and Measures
Incident outcome events were defined as the date of first inpatient hospital admission based on primary or secondary discharge diagnosis
Category | None |
Sensitivity | Normal - Content that is suitable for ages 16 and over |
Warning - This video exceeds your sensitivity preference!
To dismiss this warning and continue to watch the video please click on the button below.
Note - Autoplay has been disabled for this video.